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metformin therapy, increased glucagon
and decreased glucogenic precursors
may maintain glucose production to
prevent hypoglycemia.
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The therapeutic mechanism of metformin action re-
mains incompletely understood. Whether metformin
inhibits glucagon-stimulated endogenous glucose
production (EGP), as in preclinical studies, is unclear
in humans. To test this hypothesis, we studied nine
prediabetic individuals using a randomized, pla-
cebo-controlled, double-blinded, crossover study
design.Metformin increasedglucose tolerance, insu-
lin sensitivity, and plasma glucagon. Metformin did
not alter average basal EGP, although individual vari-
ability in EGP correlated with plasma glucagon. Met-
formin increasedbasal EGP in individuals with severe
hyperglucagonemia (>150 pg/ml). Decreased fasting
glucose after metformin treatment appears to in-
creaseglucagon to stimulateEGPandprevent further
declines in glucose. Similarly, intravenous glucagon
infusion elevated plasma glucagon (>150 pg/ml) and
stimulated a greater increase in EGP during metfor-
min therapy. Metformin also counteracted the pro-
tein-catabolic effect of glucagon. Collectively, these
data indicate that metformin does not inhibit
glucagon-stimulated EGP, but hyperglucagonemia
may decrease the ability of the metformin to lower
EGP in prediabetic individuals.INTRODUCTION
The biguanide metformin is the most commonly prescribed oral
anti-hyperglycemic agent, consumedannually byover 150million
peopleworldwide.Despitemetformin’s efficacy in loweringblood
glucose and decreasing the incidence of type 2 diabetes mellitus
(T2DM) (Knowler et al., 2002), its mechanisms of action remain
incompletely understood. In T2D individuals, metformin lowers
blood glucose by decreasing endogenous glucose production
(EGP) (DeFronzo et al., 1991; Hundal et al., 2000; Musi et al.,
2002; Stumvoll et al., 1995). Subsequent work demonstrated
that metformin acted to inhibit EGP by activating AMP-activated1394 Cell Reports 15, 1394–1400, May 17, 2016 ª 2016 The Authors
This is an open access article under the CC BY license (http://creativeprotein kinase (AMPK) (Shaw et al., 2005; He et al., 2009). How-
ever, metformin reduced EGP in AMPK knockout mice, chal-
lenging the notion that AMPK is required for decreased EGP by
metformin (Foretz et al., 2010). However, these authors utilized
supra-pharmacologic doses of metformin, and Cao et al. (2014)
subsequently demonstrated thatpharmacologicdosesofmetfor-
mincould indeed inhibit hepatic gluconeogenesis.Metforminwas
also recently discovered to decrease glucagon-induced glucose
production (Miller et al., 2013) and diminish the use of gluconeo-
genic metabolites for glucose production by altering mitochon-
drial glycerophosphate dehydrogenase and the cellular redox
status in the liver (Madiraju et al., 2014). Moreover, metformin
was recently shown to impart decreased fasting glucose and he-
patic glucoseproduction through the intestines (Ducaet al., 2015;
Buse et al., 2016). Therefore, several lines of evidence suggest
thatmetformin lowers EGPby independent or perhaps combined
mechanisms that change rate-limiting gluconeogenic enzyme
levels (He et al., 2009; Foretz et al., 2010), decrease glucagon ac-
tion (Miller et al., 2013), or limit the conversion of gluconeogenic
substrates (e.g., lactate, alanine, amino acids [AAs]) to glucose
(DeFronzoet al., 1991;Madiraju et al., 2014; Stumvoll et al., 1995).
Although preclinical models have provided clues regarding
how metformin may elicit its therapeutic effect, translating these
mechanisms to the clinical situation has been difficult because
many studies have used supra-pharmacologic dosing schemes
and biguanide derivatives contraindicated for human use (He
et al., 2009; He and Wondisford, 2015). Furthermore, metformin
may also influence glucogenic precursors and insulin sensitivity
through its influence on amino acid kinetics, a possibility
that has yet to be explored in humans. Therefore, we investi-
gated whether metformin, at therapeutic doses, would inhibit
glucagon-stimulated EGP and AA kinetics in humans. We con-
ducted a randomized, placebo-controlled, double-blinded
crossover study in prediabetic individuals and measured EGP
and AA kinetics using stable isotope methodology under basal,
glucagon-deficient, and glucagon-stimulated conditions.
RESULTS AND DISCUSSION
Nine participants completed the study (physical characteristics
are shown in Table S1). Seven had a family history of T2DM,
and eight were metformin-naive. One participant had previouslycommons.org/licenses/by/4.0/).
used metformin but discontinued it more than 2 years before the
study commenced. Some participants were taking antidepres-
sant medications (n = 5), statins (n = 3), b-blockers (n = 1), or di-
uretics (n = 1) through the entire study, and these participants did
not differ in their response to metformin therapy.
Metformin and a placebo were prescribed at a dose of 500 mg
twice daily during the first week and 1,000 mg twice daily during
the second week. On the basis of returned pill counts, subjects
adhered to the prescribed doses with a compliance rate of
99% and 94% during week 1 and 96% and 94% during week
2 for metformin and the placebo, respectively. Four participants
reported gastrointestinal discomfort, three of which occurred
during metformin treatment. Body weight and composition re-
mained unchanged during the 2-week study (Table S1).
Compared with the placebo, metformin-treated patients had
lower mean fasting plasma glucose, insulin, and c-peptide levels
but markedly higher mean plasma glucagon levels (Figure 1; Ta-
ble 1). The insulin-to-glucagon ratio and the homeostasis model
assessment of insulin resistance (HOMA-IR) were decreased by
metformin (Figures 1A and 1B).
Whole-body insulin sensitivity, b cell responsivity, and disposi-
tion index (DI) were modeled following consumption of a mixed
meal (600 kcal; 30% carbohydrate, 55% fat, 15% protein) (Fig-
ure S1). Insulin sensitivity (SI) was significantly improved by met-
formin (Figure 1C). Although b cell responsivity (F, FD, FS)
was unaltered (Figure 1D), total, dynamic, and static Dis) (DID;
DIS, -the product of b cell responsivity and SI; Figure 1E) were
significantly improved by metformin. The 2-fold increase in
whole-body insulin sensitivity was markedly greater than the
decrease inHOMA-IR,whichmaysuggest that theeffects ofmet-
formin aremore robust in response to the physiological challenge
of a high-fat mixed meal. After the meal, metformin decreased
(p < 0.01) the area above baseline for glucose, c-peptide, and in-
sulin (Figures 1F–1H). In addition to increasing postabsorptive
plasma glucagon, metformin increased (p < 0.01) postprandial
plasma glucagon at 120, 180, and 240 min (Figure 1I).
Although metformin improved glucose regulation and whole-
body insulin sensitivity based on the oral minimal model, its ef-
fect on basal EGPwas variable depending on the basal glucagon
level (Figures 2A–2C). Subtle changes in glucagon have been
shown to have profound effects on hepatic glucose metabolism
(Roden et al., 1996). Of interest, participants with basal glucagon
levels <150 pg/ml (n = 6 of 9 experienced a decrease; p = 0.01,
Cohen’s d = 0.61) in EGP, whereas participants with basal
glucagon levels >150 pg/ml (n = 3 of 9) experienced an increase
(p = 0.02, Cohen’s d = 1.26) in EGP after metformin treatment
(Figure 2C). This accounts for the lack of overall change in
mean EGP by metformin in our study (Figure 2A). It is possible
that the improvement in glucose tolerance and insulin sensitivity
occurred because of other mechanisms of action, such as the in-
fluence of metformin in the gut (Duca et al., 2015; Buse et al.,
2016), because this study has not identified the mechanism of
action by which metformin improves indices of insulin action.
Previous reports that administered metformin over a longer
period have indicated that metformin lowers basal EGP in
T2DM (Hundal et al., 2000; Stumvoll et al., 1995), but we found
that, in prediabetic humans, the decline in EGP was prevented
by a compensatory increase in glucagon levels. These findingssuggest that a compensatory increase in glucagon antagonizes
metformin’s inhibitory effect on EGP and may be involved in the
delayed or lack of response to metformin by some patients.
Studies combining metformin therapy with glucagon-like pep-
tide 1 (GLP1) agonists or dipeptidyl peptidase 4 (DPP4) inhibitors
have demonstrated a synergetic effect in achieving glycemic
control (Zander et al., 2001; DeFronzo et al., 2009; Solis-Herrera
et al., 2013) in T2DM, but it remains to be determined whether
such a combination prevents the compensatory glucagon in-
crease and increases the odds of hypoglycemic episodes in
pre-diabetic individuals.
We also examined the effect of metformin on whole-body pro-
tein metabolism because amino acids and their metabolites may
affect insulin sensitivity (Everett et al., 1981; Nair et al., 1992;
Newgard, 2012) and play a key role in determining gluconeogen-
esis through regulating substrate availability (Felig et al., 1975).
To study amino acid metabolism, we used di-labeled leucine
(1-13C, 15N leucine) to comprehensively assess leucine carbon
and nitrogen flux, transamination, reamination, and oxidation
(Table 1). During the basal period, metformin increased leucine
transamination (6%, p = 0.046) and reamination (15%, p =
0.02) but did not alter leucine carbon flux (representing leucine
appearance from endogenous protein degradation), nitrogen
flux, or oxidation (Table 1). These results corroborate previous
reports that leucine transamination is influenced by insulin treat-
ment and glycemic control in diabetic individuals (Halvatsiotis
et al., 2002; Nair et al., 1995). Such anabolic effects reduce the
availability of amino moieties for synthesis of glucose precursors
(e.g., alanine and glutamine) (Galim et al., 1980; Haymond and
Miles, 1982). In addition to measuring amino acid kinetics, we
quantitatively profiled systemic AA metabolites in plasma. There
were 16metabolites influenced bymetformin, including elevated
metabolites of the urea pathway (e.g., arginine and citrulline [p <
0.001] and ornithine [p = 0.003]). These results suggest that met-
formin treatment affects amino acid metabolites involved in
ammonia disposal. The targeted amino metabolite profiling
also revealed a decline in gluconeogenic AAs (p = 0.011) and
specific metabolites such as glutamic acid, proline, alanine,
isoleucine, alloisoleucine, and a-amino-N-butyric acid (p <
0.05), which are all involved in subsequent transamination and
gluconeogenic pathways (Table S2). We also noted that metfor-
min did not affect concentrations of essential AAs, which are
derived fromwhole-body protein degradation in the fasted state.
These findings are supported by our results showing that metfor-
min did not affect leucine carbon flux derived from endogenous
protein degradation. Previous findings in a pre-clinical model
indicated that metformin lowers basal EGP by diminishing the
use of gluconeogenic substrates (Madiraju et al., 2014).
Conversely, we show that metformin decreases glucose pre-
cursors, likely from increased utilization to preserve EGP in
prediabetic individuals. An advantage of metformin over other
glucose-lowering agents is the minimal risk of hypoglycemia.
The prediabetic model allowed us to study individuals at high
risk of developing T2D but without very high glucose levels
comparedwith thosewith overt T2D. This gave us an opportunity
to identify decreased glucogenic precursors and increased
plasma glucagon as likely mechanisms by which the glucose-
lowering effect of metformin does not result in hypoglycemia.Cell Reports 15, 1394–1400, May 17, 2016 1395
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Figure 1. Metformin Improves Fasting and
Postprandial Indices of Insulin Sensitivity
(A and B) HOMA-IR (A) and insulin-to-glucagon
ratio (B).
(C) Whole-body SI.
(D and E) b Cell responsivity (D) and disposition
index (E) modeled after a mixed-meal challenge.
(F–I) Basal and postprandial plasma values and
area above baseline (AAB) after 2 weeks of
metformin compared with placebo for glucose (F),
C-peptide (G), insulin (H), and glucagon (I). Post-
prandial glucagon was decreased with metformin
at 120, 180, and 240 min.
*p < 0.05, **p < 0.01, ***p < 0.001 metformin versus
placebo. Data are presented as mean ± SEM.
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Table 1. Hormones, Leucine Kinetics, and Resting Energy Expenditure
Placebo Metformin
Basal Somatostatin Glucagon Basal Somatostatin Glucagon
Glucose (mg/dl) 108 ± 3 103 ± 7a 214 ± 8b 93 ± 3c 85 ± 10a,c 212 ± 10b
Glucagon (pg/ml) 90.7 ± 10.0 54.3 ± 7.5a 157.1 ± 7.7b 119.1 ± 13.5 60.2 ± 6.9a 156.6 ± 11.5b
Insulin (mU/ml) 13.2 ± 1.4 0.53 ±0.06a 5.4 ± 1.4b 11.4 ± 1.5c 0.46 ± 0.05a 4.7 ± 0.5
C-peptide (nmol/l) 1.31 ± 0.09 0.33 ± 0.02a 0.46 ± 0.03b 1.13 ± 0.08c 0.28 ± 0.02a,c 0.38 ± 0.03b,c
Leucine C flux 95.0 ± 4.2 89.6 ± 3.5a 85.5 ± 4.0b 93.0 ± 1.7 90.2 ± 2.0a 87.6 ± 2.4
Leucine oxidation 19.9 ± 1.2 16.5 ± 1.2a 23.7 ± 1.7b 18.3 ± 0.8 16.4 ± 0.7 19.8 ± 1.3b,c
Leucine protein synthesis 75.1 ± 3.8 73.2 ± 3.5a 61.8 ± 3.5b 74.7 ± 2.0 73.8 ± 2.0a 67.8 ± 2.0b,c
Leucine N flux 155.0 ± 6.3 197.9 ± 7.5a 215.1 ± 12.5b 159.3 ± 6.2 204.7 ± 6.1a 230.4 ± 9.4b
Leucine transamination 79.9 ± 4.2 124.8 ± 7.1a 149.8 ± 10.2b 84.5 ± 4.7c 130.9 ± 4.6a 165.0 ± 7.8b
Leucine reamination 60.0 ± 4.2 108.3 ± 4.2a 126.1 ± 10.0b 66.3 ± 4.7c 114.5 ± 4.6a 145.2 ± 7.3b,c
% Flux oxidized 21.0 ± 1.3 18.5 ± 1.5a 27.9 ± 2.0b 19.7 ± 1.0 18.2 ± 0.8a 22.5 ± 1.1b,c
REE (kcal/day) 1669 ± 138 1682 ± 122 1925 ± 139b 1727 ± 103 1719 ± 93 1858 ± 97
RER 0.82 ± 0.01 0.75 ± 0.02 0.78 ± 0.02 0.82 ± 0.01 0.74 ± 0.02 0.75 ± 0.02
Data are expressed as micromoles per kilogram of FFM per hour for whole-body leucine kinetics. Data are represented as mean ± SE.
ap < 0.05 somatostatin versus basal.
bp < 0.05 glucagon versus somatostatin.
cp < 0.05 metformin versus placebo.To further investigate the interaction between metformin
treatment and glucagon, we continuously infused somato-
statin for 2 hr to suppress endogenous glucagon and insulin
secretions (Figure S1). Following a period of low glucagon
and insulin levels, we added a continuous infusion of glucagon
to the somatostatin infusion for 3 hr to raise plasma glucagon
levels to near those observed in participants with basal hyper-
glucagonemia (>150 pg/ml). Somatostatin was infused to pre-
vent insulin secretion in response to glucagon administration.
This study design allowed us to test the hypothesis that met-
formin antagonizes glucagon-mediated glucose production as
reported in preclinical studies. Glucagon and insulin plasma
concentrations during the somatostatin and somatostatin +
glucagon infusions were not different between metformin
and placebo treatments, whereas c-peptide levels were
marginally lower (p < 0.05) with metformin (Table 1). The
plasma metformin concentration was 1.74 ± 0.12 mM during
glucagon infusions. By design, EGP was lower (p < 0.05)
under glucagon-deficient and higher (p < 0.001) under
glucagon-stimulated conditions compared with the basal
state (Figure 2A). EGP was not different with metformin during
glucagon-deficient stages. The primary effect of metformin on
EGP occurred during glucagon infusion. Specifically, the
change in EGP from baseline was greater with metformin
compared with the placebo (1.3 ± 0.4 mmol/kg of fat-free
mass [FFM]/min, p = 0.017) (Figure 2D). A prevailing hypothe-
sis is that metformin improves glucose regulation by inhibiting
glucagon-stimulated glucose production. In support, studies
in hepatocytes and mice indicate that biguanides inhibit
glucagon signaling to mitigate hepatic glucose production
(Miller et al., 2013). However, these preclinical models
included phenformin and supratherapeutic doses of metfor-
min to inhibit glucagon action. This study included prediabetic
adults consuming therapeutic doses of the only Food andDrug Administration-approved biguanide. Our results indicate
that metformin does not inhibit glucagon-stimulated EGP in
patients with prediabetes.
In addition to EGP, leucine AA kinetics were largely altered by
somatostatin and further changed by the addition of glucagon
infusion (Table 1). Importantly, somatostatin infusion with the
accompanying decline in insulin and glucagon reduced leucine
oxidation (absolute and percent of leucine flux). However,
increasing glucagon levels increased leucine oxidation, trans-
amination, and reamination while decreasing protein synthesis.
These effects of glucagon are congruent with our previous
data in healthy individuals (Nair et al., 1987) and those with
type 1 diabetes (Charlton and Nair, 1998). The glucagon-induced
increase in leucine oxidation (p = 0.01) and decrease in protein
synthesis (p = 0.03) were attenuated by metformin treatment
(Table 1). During placebo treatment, glucagon, as previously re-
ported, increased resting energy expenditure (Nair et al., 1984),
but the glucagon effect on resting energy expenditure was
not observed during metformin treatment (Table 1). These data
suggest that metformin counteracts the catabolic effects of
glucagon by attenuating both the increase in leucine oxidation
and energy expenditure and the decrease in protein synthesis.
Glucagon secretion is well known to increase to prevent hypo-
glycemia, and plasma glucagon levels are high in the diabetic
states (Felig et al., 1976). Thus, these results show that the
potential adverse catabolic effects of the increase in glucagon
levels (Nair et al., 1987; Pain et al., 1983) seem to be mitigated
by metformin.
We used a randomized double-blind crossover study design
to test the prevailing hypothesis that metformin would inhibit
glucagon-mediated substrate metabolism in individuals with
prediabetes. Although a sample size of nine prediabetic individ-
uals not currently on glucose-lowering medications may appear
to be a limitation of this study, this study design allowedCell Reports 15, 1394–1400, May 17, 2016 1397
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Figure 2. Endogenous Glucose Production after Metformin Treatment in Prediabetic Individuals
(A) EGP under basal, glucagon-deficient (somatostatin), and glucagon-stimulated conditions (glucagon).
(B) Fasted plasma glucagon.
(C) Relationship between the change in basal EGP to basal, fasting glucagon after metformin treatment.
(D) The difference in EGP (D EGP) under glucagon-deficient (somatostatin) and glucagon-stimulated (glucagon) conditions versus basal EGP.
*p < 0.05 metformin versus placebo. Data are presented as mean ± SEM.the detection of meaningful changes in glucose and glucagon
while using gold standard approaches to assess glucogenic
metabolites and endogenous glucose production. Additional
participant groups including obese and normoglycemic individ-
uals and patients with overt T2D may have allowed further
comparisons with people with normal glucose levels and
severe hyperglycemia. Future studies might consider further
addressing the relationship between metformin, glucagon,
and glycemic control using larger sample sizes and diverse
participant populations.
CONCLUSION
With the prospect of developing alternative or improved thera-
pies to counter T2D worldwide, understanding the therapeutic
action of metformin in humans is critical. This study offers insight
into the effects of metformin in prediabetic individuals. We
demonstrated that metformin may affect glucagon-mediated
AA metabolism and energy expenditure, but, in contrast to pre-
vailing hypotheses, we found no inhibitory effect of metformin on
glucagon-induced EGP. In this study, EGP during hyperglucago-
nemia was actually greater with metformin compared with the
placebo. Therefore, the effect of metformin on EGP depends
on plasma glucagon levels so that any inhibitory effect of metfor-
min on EGP was neutralized at high basal glucagon levels or
during glucagon infusion studies. This study provides insight,
in humans, that high glucagon levels antagonize the ability of
metformin to suppress EGP, disputing a previous report in pre-
clinical models (Miller et al., 2013). These findings provide the
impetus for further study to determine whether glucagon may
be a biomarker used during metformin therapy to improve
precision medicine to stop the progression of prediabetes to
overt T2D.
EXPERIMENTAL PROCEDURES
This study was approved by theMayo Clinic Institutional Review Board, and all
subjects gave written, informed consent. This study was conducted at the
Mayo Clinic from December 2013 to December 2014 and is registered at
ClinicalTrials.gov (NCT01956929).1398 Cell Reports 15, 1394–1400, May 17, 2016Study Participants
Inclusion criteria were as follows: obesity (BMI >30 kg/m2), sedentary (<1 hr of
structured activity per week), nonsmoking, and not taking any medication to
control blood glucose. Qualifying participants (n = 33) had a medical history
and physical examination, including a blood test, after an overnight fast to
measure glucose, hemoglobin A1c, and chemistry profile. As recommended
by the American Diabetes Association in 2014 (American Diabetes Associa-
tion, 2014), participants with plasma glucose between 100–125 mg/dl or
hemoglobin A1c of 5.7%–6.4% (5.93 ± 1.16) were considered prediabetic
and were eligible for the study.
Randomization and Study Intervention
The study was a randomized double-blind crossover trial with a >6-week
washout period between interventions. Participants were randomized for a
two-treatment, two-period crossover design using permuted block randomi-
zation. Block sizes of two and eight were used to assign participants to a treat-
ment sequence of placebo followed bymetformin or vice versa. Assignment of
treatment sequences to participants was accomplished through the central
research pharmacy to preserve the blind for study investigators. Participants
were instructed to not change their diet, physical activity, or medications for
the entirety of the study. Participants were directed to take the study medica-
tion with the morning and evening meals (week 1, 500 mg twice daily; week 2,
1,000 mg twice daily). The 1,000-mg, twice daily dose was continued during
the inpatient study days (Figure S1). Metformin and placebo capsules were
matched for size and color. Participants received extra capsules so that
returned pills could be counted to determine compliance. Resting energy
expenditure (REE) and body composition were measured during an outpatient
visit before the three consecutive inpatient study days in the clinical research
unit (CRU). Inpatient visits were repeated after the second intervention.
Diet and Inpatient Study Preparation
Participants were provided a weight-maintaining diet with a standardized
macronutrient composition (50% carbohydrate, 30% fat, and 20% protein)
for 3 days before and during the inpatient study days. Participants were
admitted to the CRU the evening before each inpatient study day and
consumed their evening meal and medication by 19:00 (Figure S1).
Study Outcomes
The primary study outcomes were basal and glucagon-stimulated EGP.
Secondary outcomes included AA kinetics and results from the mixed meal
tolerance test.
Mixed Meal Tolerance Test
Insulin sensitivity (SI); total, dynamic, and static b cell responsivity (F, FD, and
FS); and DIs (DID and DIS) were modeled after a mixed meal (600 kcal; 30%
carbohydrate, 55% fat, and 15% protein) (Cobelli et al., 2014).
Glucose and AA Metabolism
EGP and whole-body AA kinetics (i.e., flux, transamination, reamination, and
oxidation) were determined on day 2 during a 2-hr basal period, a 2-hr period
of somatostatin infusion (93 ng/kg of FFM/min to suppress pancreatic hor-
mone secretion), and a 3-hr period of continuously glucagon (3 ng/kg of
FFM/min to elevate plasma glucagon) plus somatostatin, as previously
described (Charlton and Nair, 1998; Charlton et al., 1996; Nair et al., 1987).
EGP and AA kinetics were measured by an isotope-dilution technique using
a priming bolus of [13C]sodium bicarbonate concomitant with primed-contin-
uous infusions of [6,6-2H2]glucose and [1-
13C,15N]leucine (Charlton et al.,
1996; Charlton and Nair, 1998; Nair et al., 1995). Whole-body REE and respi-
ratory exchange ratio (RER) were assessed by indirect calorimetry for 20 min
during each period. Arterialized venous blood and expired air were collected
hourly and every 10 min during the last 30 min of each period.
Measurement of Hormones and Metabolites
Plasma glucose, insulin, c-peptide, and glucagon concentrations were
measured as previously described (Lalia et al., 2015). Plasma enrichment of
the infused stable isotopes and [13C]a-ketoisocaproic acid, the transaminated
product of leucine, was measured using gas chromatography-mass spec-
trometry (GC-MS). The isotope enrichment of 13CO2 in expired air was
measured by isotope-ratio mass spectrometry (Charlton and Nair, 1998;
Charlton et al., 1996; Nair et al., 1987, 1995). AA metabolites in plasma were
analyzed using liquid chromatography-tandem mass spectrometry and GC-
MS (Lanza et al., 2010).
Sample Size and Statistical Analysis
A modified intention-to-treat analysis was conducted for this study. Although
12 participants were randomized, only 11 participants initiated the study. Two
participants did not complete the crossover design, and their samples were
not analyzed along with other participants because of cost constraints. To
avoid assay batch effects, a decision was made to not include these data in
the final analysis. As such, data on the nine completing subjects were analyzed
using SAS (version 9.4) according to the principles of a two-period, two-treat-
ment crossover study with no assumed carryover effect. Models with a period
effect were found to not suggest a significant period effect, so final results
without a period effect are presented. In addition to testing for differences at
each of the three time points (basal, somatostatin infusion, and glucagon infu-
sion), the incremental change in values (i.e., somatostatin–basal and
glucagon–basal at each treatment visit) was tested to address the change in
baseline values during the two study visits. Data are presented as mean with
95% confidence intervals or SE with p values provided. Statistical significance
was set at p < 0.05.
SUPPLEMENTAL INFORMATION
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